To study the side effects and effectiveness effects of Tablet Ribociclib in hormone positive , HER2 negative breast cancer patients
Not Applicable
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2024/01/061744
- Lead Sponsor
- ot applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Patients with histopathologically confirmed ER or PR positive and HER2 negative locally advanced or metastatic breast cancer
2 Patients who have been started on Ribocliclib with atleast one record of treatment with Ribociclib from the year Jun 2018 till December 2022 will be included in study. Data will be collected from the EMR
Exclusion Criteria
1.Patient with HER2 positive metastatic cancer.
2.Patients with no available data on EMR.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study efficacy including Progression Free Survival and Overall SurvivalTimepoint: 12 months
- Secondary Outcome Measures
Name Time Method To study safety and toxicity.Timepoint: 12 months